Skip to content
EN
EN FR NL
  • About
    • About BIG
    • Strategy statement
    • BIG history
    • Governance
    • Honorary President
    • BIG HQ
    • Careers
    • Annual report
    • Contact us
  • Research
    • Research principles
    • Trials and programmes
    • EU Programmes
      • TRANSBIG
      • EURECA
      • INTEGRATE
    • Achievements
    • Translational research
    • Peer-reviewed articles
  • Members & Partners
    • BIG network
    • Collaborations
      • Patient advocates
      • BIG-NCTN
      • Industry
    • Foundations
    • Our corporate partners
      • Become a corporate partner
  • News
    • Updates
    • BIG Research in Focus
    • Press Room
  • BIG against breast cancer
    • About
    • Martine Piccart
    • BIG ambassadors
    • Events
    • Donate
    • Fundraise
    • BIG Missing campaign
  • Members login
Menu
  • About
    • About BIG
    • Strategy statement
    • BIG history
    • Governance
    • Honorary President
    • BIG HQ
    • Careers
    • Annual report
    • Contact us
  • Research
    • Research principles
    • Trials and programmes
    • EU Programmes
      • TRANSBIG
      • EURECA
      • INTEGRATE
    • Achievements
    • Translational research
    • Peer-reviewed articles
  • Members & Partners
    • BIG network
    • Collaborations
      • Patient advocates
      • BIG-NCTN
      • Industry
    • Foundations
    • Our corporate partners
      • Become a corporate partner
  • News
    • Updates
    • BIG Research in Focus
    • Press Room
  • BIG against breast cancer
    • About
    • Martine Piccart
    • BIG ambassadors
    • Events
    • Donate
    • Fundraise
    • BIG Missing campaign
  • Members login
  • About
    • About BIG
    • Strategy statement
    • BIG history
    • Governance
    • Honorary President
    • BIG HQ
    • Careers
    • Annual report
    • Contact us
  • Research
    • Research principles
    • Trials and programmes
    • EU Programmes
      • TRANSBIG
      • EURECA
      • INTEGRATE
    • Achievements
    • Translational research
    • Peer-reviewed articles
  • Members & Partners
    • BIG network
    • Collaborations
      • Patient advocates
      • BIG-NCTN
      • Industry
    • Foundations
    • Our corporate partners
      • Become a corporate partner
  • News
    • Updates
    • BIG Research in Focus
    • Press Room
  • BIG against breast cancer
    • About
    • Martine Piccart
    • BIG ambassadors
    • Events
    • Donate
    • Fundraise
    • BIG Missing campaign
  • Members login
Menu
  • About
    • About BIG
    • Strategy statement
    • BIG history
    • Governance
    • Honorary President
    • BIG HQ
    • Careers
    • Annual report
    • Contact us
  • Research
    • Research principles
    • Trials and programmes
    • EU Programmes
      • TRANSBIG
      • EURECA
      • INTEGRATE
    • Achievements
    • Translational research
    • Peer-reviewed articles
  • Members & Partners
    • BIG network
    • Collaborations
      • Patient advocates
      • BIG-NCTN
      • Industry
    • Foundations
    • Our corporate partners
      • Become a corporate partner
  • News
    • Updates
    • BIG Research in Focus
    • Press Room
  • BIG against breast cancer
    • About
    • Martine Piccart
    • BIG ambassadors
    • Events
    • Donate
    • Fundraise
    • BIG Missing campaign
  • Members login
Donate
BIG Members
EN
EN FR NL

Press Release

SOLE (Study of Letrozole Extension):A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer

Primary results of LORELEI study presentedat ESMO 2017 Congress

PANACEA study suggests immunotherapy may help to overcome trastuzumab-resistant breast cancer

Ovarian Suppression Reduces Recurrence for Young Breast Cancer Patients

1 out of 3 men with breast cancer does not receive adequate treatment

Belgium has the highest incidence of breast cancer in the world!

Progress in the fight against metastatic breas cancer

The BIG Radio Tuning clinical study

Breast cancer prevention – significant progress: 49% reduction in breast cancer occurrence with anastrozole (long-term follow up results of the IBIS II Prevention trial)

Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib

Page1 Page2 Page3 Page4

Breast international group (BIG) – aisbl

Rue de bretagne 20,
1200 Brussels, Belgium
VAT BE 0468 176 240
IBAN BE08 0689 0916 0213

Facebook-f Twitter Instagram Linkedin Youtube Flickr

Navigation

  • About
  • Research
  • News
  • Support research
  • Press room
  • Contact us
  • Privacy policy
  • FAQ
AERFLABELPMSDEFVblanc

The Breast International Group is proud to adhere
to the Code of Ethics of the VEF-AERF

© 2022 All rights reserved

Breast international group (BIG) - aisbl